Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
NCT ID: NCT04553458
Last Updated: 2020-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
407 participants
OBSERVATIONAL
2015-06-30
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
NCT03097848
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
NCT02187081
HR Versus RFA for Early Stage HCC
NCT02169765
Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC
NCT03806218
Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
NCT03988998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus \< = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma (HCC) who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.
Methods:
This work was conducted at the departments of tropical medicine and gastroenterology, internal medicine, and general surgery. This study included patients that matched our eligibility criteria for a period of five years started from June 2015 to May 2020. The study purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment favorable outcomes. The data of the patients were extracted and retrospectively reviewed from the patients' records and the databases of both hospitals (SUH and SOI).
During the period of recruitment, 407 patients diagnosed with HCC admitted to our departments and followed-up attending outpatient clinics, Sohag University Hospitals, over a 5 years period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Favorable outcome
Cure or stable disease
Radiofrequency ablation
Radiofrequency ablation of the tumour
Trance-arterial chemoembolization
Trance-arterial chemotherapy
Liver resection
non-anatomical or anatomical liver resection
Combined radiofrequency ablation + percutaneous ethanol injection
combined therapy
Percutaneous ethanol injection
Percutaneous ethanol injection of HCC
Unfavorable outcome
Progressive (deteriorate/Recurrence) or Death
Radiofrequency ablation
Radiofrequency ablation of the tumour
Trance-arterial chemoembolization
Trance-arterial chemotherapy
Combined radiofrequency ablation + percutaneous ethanol injection
combined therapy
Percutaneous ethanol injection
Percutaneous ethanol injection of HCC
Systemic chemotherapy
Systemic chemotherapy
Sorafenib
Sorafenib
Viscum
Viscum for HCC
Symptomatic treatment
Symptomatic treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiofrequency ablation
Radiofrequency ablation of the tumour
Trance-arterial chemoembolization
Trance-arterial chemotherapy
Liver resection
non-anatomical or anatomical liver resection
Combined radiofrequency ablation + percutaneous ethanol injection
combined therapy
Percutaneous ethanol injection
Percutaneous ethanol injection of HCC
Systemic chemotherapy
Systemic chemotherapy
Sorafenib
Sorafenib
Viscum
Viscum for HCC
Symptomatic treatment
Symptomatic treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with hepatocellular carcinoma
Exclusion Criteria
* With other system comorbidities,
* presence of extrahepatic metastasis,
* patients who dropped from the follow-up list after treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emad Ali Ahmed Ali
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emad A. Ahmed, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Sohag University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22/09/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.